These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Allergic contact dermatitis from apraclonidine. Armisen M; Vidal C; Quintans R; Suarez A; Castroviejo M Contact Dermatitis; 1998 Oct; 39(4):193. PubMed ID: 9817226 [No Abstract] [Full Text] [Related]
28. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery. Dahlmann-Noor AH; Cosgrave E; Lowe S; Bailly M; Vivian AJ J AAPOS; 2009 Apr; 13(2):123-6. PubMed ID: 19393510 [TBL] [Abstract][Full Text] [Related]
29. Selectivity of site of action and systemic effects of topical alpha agonists. Robin AL; Burnstein Y Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510 [TBL] [Abstract][Full Text] [Related]
30. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group. Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299 [TBL] [Abstract][Full Text] [Related]
31. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871 [TBL] [Abstract][Full Text] [Related]
32. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690 [TBL] [Abstract][Full Text] [Related]
34. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye. Carrasco MA; Schlaen BA; Zárate JO Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363 [TBL] [Abstract][Full Text] [Related]
35. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
36. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost]. Gebhardt DO Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159 [No Abstract] [Full Text] [Related]
37. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost]. Hoyng PF; Rasker MT Ned Tijdschr Geneeskd; 1998 Sep; 142(39):2138-41. PubMed ID: 9856229 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. thoe Schwartzenberg GW; Buys YM Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912 [TBL] [Abstract][Full Text] [Related]
39. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy. Lee JS; Kim CY Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740 [TBL] [Abstract][Full Text] [Related]
40. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Osborne SA; Montgomery DM; Morris D; McKay IC Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]